Terms: = Endocrine gland cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
440 results:
1. Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model.
Imran KM; Brock RM; Beitel-White N; Powar M; Orr K; Aycock KN; Alinezhadbalalami N; Salameh ZS; Eversole P; Tintera B; Markov Madanick J; Hendricks-Wenger A; Coutermarsh-Ott S; Davalos RV; Allen IC
Front Immunol; 2024; 15():1352821. PubMed ID: 38711517
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of PD-1/pd-l1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
3. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
[TBL] [Abstract] [Full Text] [Related]
4. The nanobody targeting pd-l1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract] [Full Text] [Related]
5. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
6. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer.
Li Z; Mo F; Guo K; Ren S; Wang Y; Chen Y; Schwartz PB; Richmond N; Liu F; Ronnekleiv-Kelly SM; Hu Q
Med; 2024 Apr; 5(4):348-367.e7. PubMed ID: 38521069
[TBL] [Abstract] [Full Text] [Related]
7. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
[TBL] [Abstract] [Full Text] [Related]
8. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences pd-l1 Expression in Papillary Thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
9. 4-Hydroxyphenylpyruvate Dioxygenase-Like predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.
Li H; Liu J; Wang S; Xu Y; Tang Q; Ying G
Aging (Albany NY); 2024 Mar; 16(5):4327-4347. PubMed ID: 38451188
[TBL] [Abstract] [Full Text] [Related]
10. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way.
Balar PC; Apostolopoulos V; Chavda VP
Eur J Pharmacol; 2024 Apr; 969():176451. PubMed ID: 38408598
[TBL] [Abstract] [Full Text] [Related]
11. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract] [Full Text] [Related]
12. Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis.
Chen Y; Zhang F; Zhang B; Trojanowicz B; Hämmerle M; Kleeff J; Sunami Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1990. PubMed ID: 38389400
[TBL] [Abstract] [Full Text] [Related]
13. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
[TBL] [Abstract] [Full Text] [Related]
14. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells.
Wang J; Gai J; Zhang T; Niu N; Qi H; Thomas DL; Li K; Xia T; Rodriguez C; Parkinson R; Durham J; McPhaul T; Narang AK; Anders RA; Osipov A; Wang H; He J; Laheru DA; Herman JM; Lee V; Jaffee EM; Thompson ED; Zhu Q; Zheng L
Sci Adv; 2024 Feb; 10(6):eadk1827. PubMed ID: 38324679
[TBL] [Abstract] [Full Text] [Related]
15. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract] [Full Text] [Related]
16. Effect of sodium stibogluconate in recruiting and awakening immune cells in the pleural fluid of pancreatic cancer: preparation for immunotherapy.
Yu B; Jing P; Gao F; Zhang P; Zheng G; Zhang X
Front Immunol; 2023; 14():1315468. PubMed ID: 38313432
[TBL] [Abstract] [Full Text] [Related]
17. Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer.
Song N; Cui K; Zeng L; Li M; Fan Y; Shi P; Wang Z; Su W; Wang H
Eur J Pharmacol; 2024 Mar; 967():176357. PubMed ID: 38309677
[TBL] [Abstract] [Full Text] [Related]
18. Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients.
Ling L; Li B; Wu H; Zhang K; Li S; Ke B; Zhu Z; Liu T; Liu P; Zhang B
J Gene Med; 2024 Jan; 26(1):e3606. PubMed ID: 38282157
[TBL] [Abstract] [Full Text] [Related]
19. Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs): A Scoping Review of 511 Cases, Including 2 New Cases.
Watrowski R; Palumbo M; Guerra S; Gallo A; Zizolfi B; Giampaolino P; Bifulco G; Di Spiezio Sardo A; De Angelis MC
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276058
[TBL] [Abstract] [Full Text] [Related]
20. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract] [Full Text] [Related]
[Next]
